"Sound Performance" Says Sanofi
Sanofi of France said that favorable growth factors in the first half of 1994 reveal a sound performance. Sales in the first half advanced 16.1% to 12.29 billion French francs ($2.33 billion). Net income amounted to 460 million francs, rising 0.9%.
The company's pharmaceutical sector benefited from renewed growth in Germany and generally good sales in other European markets, said Sanofi. The good performance and the adaptation of costs to the operating environment enabled the human health care segment to increase earnings appreciably, it added.
Sanofi's expenditure on pharmaceutical R&D rose 10.7%. The company said that this was a result of the continuation of international clinical trials. The increases exclude the impact of the agreements Sanofi has with US drug company Bristol-Myers Squibb.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze